We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
Read MoreHide Full Article
Key Takeaways
ANIP's 2025 revenue hit $883.4M, with Cortrophin Gel driving growth and Rare Disease sales up over 80% YoY.
Cortrophin generated nearly $348M in 2025, up 76% YoY, and is projected to reach $540M-$575M in 2026.
ANIP plans a 90-person gout sales force and new syringe format to boost Cortrophin adoption and growth.
ANI Pharmaceuticals (ANIP - Free Report) is reshaping its growth profile around specialty medicines, with Cortrophin Gel increasingly driving results and management’s 2026 targets. Fiscal 2025 also underscored how concentrated the business remains in the United States, even as select franchises broaden the portfolio.
With new commercial initiatives and product enhancements in motion, ANIP enters 2026 with multiple levers aimed at sustaining momentum.
ANIP’s Revenue Mix Shifts Toward Rare Disease
Fiscal 2025 total revenue reached $883.4 million, with Rare Disease and Brands contributing $484.0 million, or 54.8% of the total. Generics and Other supplied the remaining $399.4 million, or 45.2%.
Within Rare Disease and Brands, Cortrophin Gel delivered $347.8 million, while Iluvien and Yutiq contributed $74.9 million. This mix highlights how the specialty portfolio has become the core growth narrative, anchored by a single high-impact product and supported by an ophthalmology platform.
Geographically, fiscal 2025 revenue was primarily U.S.-derived, with $852.4 million generated domestically versus $30.9 million from international operations and partnerships.
ANI Pharma’s Cortrophin Gel Story in 2025
Cortrophin’s 2025 revenue came in at nearly $348 million, representing about 76% year-over-year growth. That performance was a central driver behind total sales rising roughly 44% in 2025.
The surge also aligned with Rare Disease revenue expanding more than 80% year over year, underscoring how the franchise is pulling ANIP’s overall trajectory toward higher-margin specialty therapies.
ANIP’s 2026 Guidance Sets the Growth Baseline
Management reaffirmed fiscal 2026 total net revenue guidance of $1.055 billion to $1.1 billion, establishing a clear baseline for continued top-line expansion.
For Cortrophin, ANIP guided to $540 million to $575 million of revenue in 2026, signaling expectations for another step-up in scale. Profitability targets were also raised into focus with adjusted non-GAAP EBITDA of $275 million to $290 million.
The company guided adjusted non-GAAP earnings per share of $8.83 to $9.34 and adjusted gross margin of 59.3% to 60.3%, reflecting the intended operating leverage as the specialty portfolio grows.
ANI Pharma’s Gout Sales Force Targets a Big Market
A key execution element is ANIP’s push into acute gouty arthritis flares, where the company plans a dedicated, roughly 90-person sales force buildout. The goal is to expand Cortrophin adoption by focusing on a large patient population that management views as underpenetrated.
Management commentary also indicates sequential acceleration through 2026 as the gout team is deployed mid-year, after early-year friction from insurance reverifications and winter disruptions.
ANIP’s Prefilled Syringe Boosts New Patient Starts
ANIP has also introduced a prefilled syringe formulation for Cortrophin, designed to improve ease of use for patients and providers.
The new format has already gained rapid traction and accounts for a majority of new patient starts, which reinforces the durability of uptake as prescribing expands across multiple specialties.
ANI Pharma’s Ophthalmology Unit Eyes a 2026 Rebound
In ophthalmology, 2025 results were pressured by reimbursement challenges and elevated inventory levels at physician offices, weighing on near-term performance.
ANIP expects the franchise to return to growth in 2026, supported by guidance for Iluvien revenue of $78 million to $83 million. That range implies 4% to 11% year-over-year growth and positions ophthalmology as a complementary contributor alongside Cortrophin.
ANIP’s Generics Cash Flow Supports the Strategy
While specialty therapies are shaping the growth story, Generics remains a stabilizer that helps fund the broader strategy. Generics revenue totaled $384 million in 2025, up about 28% year over year.
The segment’s model relies on targeting niche and limited-competition opportunities, supported by a cadence of 10 to 15 product launches annually and selective partnerships to enhance scale and commercialization efficiency.
ANI Pharma’s Key Risks Investors Should Track
Competitive intensity is a central risk, particularly in Rare Disease where Cortrophin faces Acthar Gel, marketed by Keenova Therapeutics, and both products are described as showing similar sales momentum.
Ophthalmology also carries competitive pressures. AbbVie (ABBV - Free Report) competes with Ozurdex across overlapping indications, while Regeneron Pharmaceuticals (REGN - Free Report) remains prominent in diabetic macular edema through Eylea and Eylea HD.
Customer concentration is another factor to monitor. In 2025, three wholesale customers accounted for 53% of total net revenues and represented 64% of accounts receivable, which can increase purchasing leverage and pressure pricing or margins over time.
View the Zacks #1 Rank List
Image: Bigstock
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
Key Takeaways
ANI Pharmaceuticals (ANIP - Free Report) is reshaping its growth profile around specialty medicines, with Cortrophin Gel increasingly driving results and management’s 2026 targets. Fiscal 2025 also underscored how concentrated the business remains in the United States, even as select franchises broaden the portfolio.
With new commercial initiatives and product enhancements in motion, ANIP enters 2026 with multiple levers aimed at sustaining momentum.
ANIP’s Revenue Mix Shifts Toward Rare Disease
Fiscal 2025 total revenue reached $883.4 million, with Rare Disease and Brands contributing $484.0 million, or 54.8% of the total. Generics and Other supplied the remaining $399.4 million, or 45.2%.
Within Rare Disease and Brands, Cortrophin Gel delivered $347.8 million, while Iluvien and Yutiq contributed $74.9 million. This mix highlights how the specialty portfolio has become the core growth narrative, anchored by a single high-impact product and supported by an ophthalmology platform.
Geographically, fiscal 2025 revenue was primarily U.S.-derived, with $852.4 million generated domestically versus $30.9 million from international operations and partnerships.
ANI Pharma’s Cortrophin Gel Story in 2025
Cortrophin’s 2025 revenue came in at nearly $348 million, representing about 76% year-over-year growth. That performance was a central driver behind total sales rising roughly 44% in 2025.
The surge also aligned with Rare Disease revenue expanding more than 80% year over year, underscoring how the franchise is pulling ANIP’s overall trajectory toward higher-margin specialty therapies.
ANIP’s 2026 Guidance Sets the Growth Baseline
Management reaffirmed fiscal 2026 total net revenue guidance of $1.055 billion to $1.1 billion, establishing a clear baseline for continued top-line expansion.
For Cortrophin, ANIP guided to $540 million to $575 million of revenue in 2026, signaling expectations for another step-up in scale. Profitability targets were also raised into focus with adjusted non-GAAP EBITDA of $275 million to $290 million.
The company guided adjusted non-GAAP earnings per share of $8.83 to $9.34 and adjusted gross margin of 59.3% to 60.3%, reflecting the intended operating leverage as the specialty portfolio grows.
ANI Pharmaceuticals, Inc. Price and Consensus
ANI Pharmaceuticals, Inc. price-consensus-chart | ANI Pharmaceuticals, Inc. Quote
ANI Pharma’s Gout Sales Force Targets a Big Market
A key execution element is ANIP’s push into acute gouty arthritis flares, where the company plans a dedicated, roughly 90-person sales force buildout. The goal is to expand Cortrophin adoption by focusing on a large patient population that management views as underpenetrated.
Management commentary also indicates sequential acceleration through 2026 as the gout team is deployed mid-year, after early-year friction from insurance reverifications and winter disruptions.
ANIP’s Prefilled Syringe Boosts New Patient Starts
ANIP has also introduced a prefilled syringe formulation for Cortrophin, designed to improve ease of use for patients and providers.
The new format has already gained rapid traction and accounts for a majority of new patient starts, which reinforces the durability of uptake as prescribing expands across multiple specialties.
ANI Pharma’s Ophthalmology Unit Eyes a 2026 Rebound
In ophthalmology, 2025 results were pressured by reimbursement challenges and elevated inventory levels at physician offices, weighing on near-term performance.
ANIP expects the franchise to return to growth in 2026, supported by guidance for Iluvien revenue of $78 million to $83 million. That range implies 4% to 11% year-over-year growth and positions ophthalmology as a complementary contributor alongside Cortrophin.
ANIP’s Generics Cash Flow Supports the Strategy
While specialty therapies are shaping the growth story, Generics remains a stabilizer that helps fund the broader strategy. Generics revenue totaled $384 million in 2025, up about 28% year over year.
The segment’s model relies on targeting niche and limited-competition opportunities, supported by a cadence of 10 to 15 product launches annually and selective partnerships to enhance scale and commercialization efficiency.
ANI Pharma’s Key Risks Investors Should Track
Competitive intensity is a central risk, particularly in Rare Disease where Cortrophin faces Acthar Gel, marketed by Keenova Therapeutics, and both products are described as showing similar sales momentum.
Ophthalmology also carries competitive pressures. AbbVie (ABBV - Free Report) competes with Ozurdex across overlapping indications, while Regeneron Pharmaceuticals (REGN - Free Report) remains prominent in diabetic macular edema through Eylea and Eylea HD.
Customer concentration is another factor to monitor. In 2025, three wholesale customers accounted for 53% of total net revenues and represented 64% of accounts receivable, which can increase purchasing leverage and pressure pricing or margins over time.
ANIP’s Zacks Rank
ANI Pharmaceuticals currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.